Cantor Fitzgerald Issues Negative Estimate for DNLI Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI) – Equities research analysts at Cantor Fitzgerald decreased their FY2025 earnings per share estimates for Denali Therapeutics in a note issued to investors on Thursday, April 10th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will earn ($3.04) per share for the year, down from their previous estimate of ($3.00). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share.

A number of other research analysts have also commented on DNLI. Morgan Stanley assumed coverage on shares of Denali Therapeutics in a research note on Friday, March 7th. They issued an “overweight” rating and a $33.00 price target on the stock. Robert W. Baird assumed coverage on Denali Therapeutics in a research report on Tuesday, January 7th. They set an “outperform” rating and a $31.00 price objective on the stock. William Blair reissued an “outperform” rating on shares of Denali Therapeutics in a research report on Friday, February 28th. JPMorgan Chase & Co. dropped their price objective on shares of Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating for the company in a research note on Tuesday, January 7th. Finally, Baird R W upgraded shares of Denali Therapeutics to a “strong-buy” rating in a research report on Tuesday, January 7th. One investment analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $37.57.

Denali Therapeutics Trading Down 0.8 %

DNLI opened at $13.17 on Monday. The stock’s fifty day simple moving average is $16.14 and its 200 day simple moving average is $21.60. Denali Therapeutics has a 1-year low of $10.57 and a 1-year high of $33.33. The stock has a market cap of $1.91 billion, a PE ratio of -4.77 and a beta of 1.58.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.08.

Institutional Investors Weigh In On Denali Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Rhumbline Advisers raised its stake in Denali Therapeutics by 0.3% during the 4th quarter. Rhumbline Advisers now owns 190,390 shares of the company’s stock worth $3,880,000 after buying an additional 497 shares during the period. PNC Financial Services Group Inc. increased its position in shares of Denali Therapeutics by 30.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company’s stock valued at $77,000 after acquiring an additional 885 shares during the last quarter. Sterling Capital Management LLC boosted its stake in Denali Therapeutics by 589.9% in the fourth quarter. Sterling Capital Management LLC now owns 1,773 shares of the company’s stock valued at $36,000 after acquiring an additional 1,516 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Denali Therapeutics by 0.8% during the 4th quarter. The Manufacturers Life Insurance Company now owns 208,521 shares of the company’s stock worth $4,250,000 after purchasing an additional 1,702 shares during the last quarter. Finally, E Fund Management Co. Ltd. raised its holdings in shares of Denali Therapeutics by 32.2% in the 4th quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company’s stock worth $204,000 after purchasing an additional 2,436 shares during the period. Institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.